NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.08. The biopharmaceutical company earned $38.02 million during the quarter, compared to the consensus estimate of $35.59 million. Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The business's revenue was up 53.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.42) EPS. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Nektar Therapeutics.

12 brokers have issued 12 month target prices for Nektar Therapeutics' shares. Their predictions range from $20.00 to $125.00. On average, they anticipate Nektar Therapeutics' share price to reach $81.1818 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Ratings for Nektar Therapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Nektar Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 16,926,100 shares, an increase of 33.4% from the May 31st total of 12,686,538 shares. Based on an average daily volume of 9,900,153 shares, the days-to-cover ratio is presently 1.7 days. Approximately 10.0% of the shares of the stock are sold short. View Nektar Therapeutics' Current Options Chain.

Some companies that are related to Nektar Therapeutics include Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Genmab A/S (GNMSF).

News headlines about NKTR stock have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.08 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.27%), Retirement Systems of Alabama (0.08%), Bank of Montreal Can (0.08%), Franklin Street Advisors Inc. NC (0.03%), Gulf International Bank UK Ltd (0.03%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Rathbone Brothers plc and Fortaleza Asset Management Inc.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Scout Investments Inc., Retirement Systems of Alabama, Franklin Street Advisors Inc. NC, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund, State of Alaska Department of Revenue and DnB Asset Management AS. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $48.36.

Nektar Therapeutics has a market capitalization of $8.19 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]